24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
Public ClinicalTrials.gov record NCT00360529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Study identification
- NCT ID
- NCT00360529
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 880 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2006 (Type not available)
- Primary completion
- Apr 2008 (Actual)
- Completion
- Apr 2008 (Actual)
- Last update posted
- Jun 27, 2016
2006 – 2008
United States locations
- U.S. sites
- 40
- U.S. states
- 24
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 511.71.01034 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 511.71.01042 Boehringer Ingelheim Investigational Site | South Birmingham | Alabama | — | — |
| 511.71.01016 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 511.71.01041 Boehringer Ingelheim Investigational Site | La Mesa | California | — | — |
| 511.71.01011 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.71.01027 Boehringer Ingelheim Investigational Site | Westlake Village | California | — | — |
| 511.71.01035 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 511.71.01010 Boehringer Ingelheim Investigational Site | Groton | Connecticut | — | — |
| 511.71.01021 Boehringer Ingelheim Investigational Site | New Britain | Connecticut | — | — |
| 511.71.01037 Boehringer Ingelheim Investigational Site | Newark | Delaware | — | — |
| 511.71.01001 Boehringer Ingelheim Investigational Site | Boynton Beach | Florida | — | — |
| 511.71.01032 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 511.71.01014 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 511.71.01025 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 511.71.01006 Boehringer Ingelheim Investigational Site | Plantation | Florida | — | — |
| 511.71.01015 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 511.71.01038 Boehringer Ingelheim Investigational Site | Marietta | Georgia | — | — |
| 511.71.01036 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 511.71.01029 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 511.71.01028 Boehringer Ingelheim Investigational Site | Renton | Indiana | — | — |
| 511.71.01024 Boehringer Ingelheim Investigational Site | New Orlean | Louisiana | — | — |
| 511.71.01040 Boehringer Ingelheim Investigational Site | Towson | Maryland | — | — |
| 511.71.01045 Boehringer Ingelheim Investigational Site | Brighton | Massachusetts | — | — |
| 511.71.01005 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 511.71.01030 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 511.71.01007 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 511.71.01012 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 511.71.01023 Boehringer Ingelheim Investigational Site | New Bern | North Carolina | — | — |
| 511.71.01002 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.71.01044 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.71.01026 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 511.71.01039 Boehringer Ingelheim Investigational Site | Edmond | Oklahoma | — | — |
| 511.71.01003 Boehringer Ingelheim Investigational Site | Danville | Pennsylvania | — | — |
| 511.71.01033 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 511.71.01031 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 511.71.01022 Boehringer Ingelheim Investigational Site | Mt. Pleasant | South Carolina | — | — |
| 511.71.01020 Boehringer Ingelheim Investigational Site | Germantown | Tennessee | — | — |
| 511.71.01017 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.71.01018 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.71.01008 Boehringer Ingelheim Investigational Site | Huntington | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00360529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2016 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00360529 live on ClinicalTrials.gov.